Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 58 for “"Apixaban"”.
-
Comparison of Apixaban and left atrial appendage exclusion device (Watchman) in preventing stroke and systemic embolism in atrial fibrillation patients
… increased risk of stroke and systemic embolism. Apixaban, an oral anticoagulant, and the Watchman, a left atrial appendage closure device, are the currently used therapeutic treatments for the prevention of stroke and systemic embolism in atrial fibrillation patients. However, a direct comparison …
-
Evaluierung der Sicherheit der kurzfristig unterbrochenen Therapie mit Apixaban, Rivaroxaban und Dabigatran hinsichtlich Blutungskomplikationen nach CIED-Implantationen oder ähnlichen Prozeduren, im Vergleich zu Phenprocoumon
… der direkten oralen Antikoagulanzien (DOAC) Apixaban, Rivaroxaban und Dabigatran war zum Zeitpunkt des Aufkommens der DOAC’s nicht klar definiert. Ziel dieser retrospektiven Analyse ist die Evaluation der Sicherheit der kurzfristig unterbrochenen perioperativen Einnahme von DOAC’s. Dies …
-
Αξιολόγηση των σφαιρικών δοκιμασιών της αιμόστασης στην ex vivo μελέτη της αντιπηκτικής και αντιαιμοπεταλιακής δράσης των νεότερων από του στόματος αντιπηκτικών και της ασενοκουμαρόλης σε ασθενείς με μη βαλβιδική κολπική μαρμαρυγή
… 20 treated with rivaroxaban 20 mg qd, 20 with apixaban 5 mg bid, 20 treated with acenocoumarol). We performed conventional coagulation tests (PT/INR, APTT, FIB), global assays reflecting the hemostatic profile [thrombin generation (TG), thromboelastometry (ROTEM)] as well as the gold standard …
-
Real-world effectiveness of oral anticoagulants in the prevention of stroke: emulation and extension of the ARISTOTLE trial using UK EHRs
… in AF by emulating the pivotal ARISTOTLE trial (apixaban vs warfarin) in linked UK primary care data before extending the analysis to study groups excluded from, or underrepresented in ARISTOTLE. METHODS: This thesis used a novel method involving simultaneous equations and sampling to select a …
-
Myeloma and Thrombosis
… is unknown. <br/><br/><b>Aims </b><br/>To assess apixaban as thromboprophylaxis in newly diagnosed multiple myeloma (NDMM) patients. This feasibility study aims to determine which biomarkers of thrombosis warrant further investigation in a larger clinical trial. Patient perspectives were sought on …
-
Geros laboratorinės praktikos principų taikymas, vykdant gydymo antikoaguliantais stebėseną anti-Xa metodu /
… test procedures of fondaparinux, rivaroxaban, apixaban and dabigatran, compared to the manufacturer's declared characteristics and, in case of positive results, to implement methods for clinical practice. Methods. An anonymous questionnaire was conducted and 31 Lithuanian doctors were …
-
Comparative and Cost-effectiveness of Stroke Prevention Treatments in Atrial Fibrillation: A New Generation of Drugs
… dabigatran (110mg and 150mg), rivaroxaban, apixaban, and edoxaban (low-dose [LD] and high-dose). Cost data were generated from a cohort of real-world AF patients identified through administrative data, to estimate the costs associated with clinical events corresponding to health states in a …
-
Ασφάλεια και αποτελεσματικότητα της απιξαμπάνης ως προς την πρόληψη θρομβοεμβολικών επεισοδίων σε ενήλικες ασθενείς με συγγενή καρδιοπάθεια και κολπική μαρμαρυγή
… aimed to assess the effectiveness and safety of apixaban in ACHD patients with atrial fibrillation. Methods: Initially, we conducted a systematic review of evidence regarding the safety and efficacy of NOACs in CHD, until 2019. We then conducted a prospective, multicenter, observational study, …
-
Circulating Extracellular Vesicles in Patients with Cancer and Venous Thromboembolism
… impact of prophylactic antithrombotic therapy (Apixaban). We hypothesized that elevated levels of circulating large EVs will be predictive of cancer associated VTE and/or bleeding events and that treatment with Apixaban will reduce EV levels and incidence of cancer VTE. Plasma samples from …
-
Clot structure and plasma microparticles in atrial fibrillation
… with lower risk for systemic thromboembolism. Apixaban, one of the four licenced NOACs for stoke prevention in NVAF, even at the higher recommended dose (5mg BID), has significantly reduced the haemorrhagic complications but there is still a considerable risk of intracranial bleeding. This MD …
-
Use of direct oral anticoagulants in Scotland
… anticoagulants (DOAC) dabigatran, rivaroxaban, apixaban and edoxaban have been introduced. However, real-world information regarding the utilisation of DOACs as well as their clinical effectiveness and safety is still scarce. Hence, the aim of this project was to increase the evidence from …
-
A review of the real-world incidence of major bleeding after anticoagulant use in atrial fibrillation patients in the United States
… assessed were generally older and male. Apixaban resulted in statistically significant reductions in bleeding risk compared to warfarin in most studies that assessed the relationship (n = 11). Dabigatran was less consistently shown to exhibit a lower bleeding risk compared to warfarin; …
-
The Role Of Clot Structure And Mechanics On Hemodynamics And Pharmacology
… device to examine the efficacy of ex vivo apixaban on platelet and fibrin deposition in neonates with CHD. This patient population was shown to have significantly more activity blood after surgery. We found that apixaban drastically lowers coagulation activity in neonatal blood before and …
-
Predicting infant exposure to direct oral anticoagulants in breastfeeding mothers
… and validated for quantifying three DOACs - apixaban, edoxaban and rivaroxaban in human plasma and breastmilk. Protein precipitation with methanol was performed for sample preparation. Chromatographic analysis was performed using a C18 column. The MS detection was performed in MRM mode. The …
-
Effects of direct active-site anticoagulants on the fibrinolytic function of coagulation factor Xa
… agents in this class of drugs, rivaroxaban and apixaban, are direct inhibitors of FXa. This dissertation addresses the effect these two DOACs have on fibrinolysis and FXa fragmentation due to their ability to block the active site of FXa. Results presented in Chapter 3 demonstrate that in normal …
-
Estimating the Impact of Adherence to Direct Oral Anticoagulants on Health Outcomes Among Patients with Atrial Fibrillation
… this study compared the cost-effectiveness of apixaban and rivaroxaban by incorporating real-world evidence. The study was comprised of 1,969 patients with AF. The adherence to DOACs was suboptimal among Medicare Advantage Plan beneficiaries. Only 36.8% were adherent during the follow-up. …
-
Η χρήση της θρομβοελαστομετρίας στη συγκριτική αξιολόγηση της αντιπηκτικής και ινωδολυτικής δράσης των νεότερων per os αντιπηκτικών σε ασθενείς με μη βαλβιδική κολπική μαρμαρυγή και ο ρόλος της στην εκτίμηση των επιπέδων των φαρμάκων αυτών στο πλάσμα
… DOACs (Dabigatran Etexilate, Rivaroxaban, Apixaban), όπως αυτή θα μετρηθεί με θρομβοελαστομετρία (ROTEM), καθώς και η συσχέτιση των παραμέτρων της θρομβοελαστομετρίας με τα μέγιστα επίπεδα των φαρμάκων αυτών στο πλάσμα. Υλικό και Μέθοδος: Στη μελέτη περιελήφθησαν 80 ασθενείς με NVAF υπό …
-
Outcomes of Direct Oral Anticoagulants in Patients with Atrial Fibrillation
… events of the most commonly prescribed DOACs, apixaban versus rivaroxaban in older patients with AF. The results showed that among AF patients 66 years or older, treatment with apixaban was associated with reduced risk of the primary composite outcome of major bleeding, thromboembolic events, …
Page 1 of 3